Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

338 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?
Heidegger I, Necchi A, Pircher A, Tsaur I, Marra G, Kasivisvanathan V, Kretschmer A, Mathieu R, Ceci F, van den Bergh RCN, Thibault C, Tilki D, Valerio M, Surcel C, Gandaglia G; EAU-YAU Prostate Cancer Working Party. Heidegger I, et al. Among authors: thibault c. Eur Urol Oncol. 2021 Oct;4(5):745-754. doi: 10.1016/j.euo.2020.10.010. Epub 2020 Nov 23. Eur Urol Oncol. 2021. PMID: 33243663 Review.
A simple HPLC-UV method for quantification of enzalutamide and its active metabolite N-desmethyl enzalutamide in patients with metastatic castration-resistant prostate cancer.
Puszkiel A, Plé A, Huillard O, Noé G, Thibault C, Oudard S, Goldwasser F, Vidal M, Alexandre J, Blanchet B. Puszkiel A, et al. Among authors: thibault c. J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Jul 15;1058:102-107. doi: 10.1016/j.jchromb.2017.04.014. Epub 2017 Apr 5. J Chromatogr B Analyt Technol Biomed Life Sci. 2017. PMID: 28545929
Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer.
Thibault C, Eymard JC, Birtle A, Krainer M, Baciarello G, Fléchon A, Le Moulec S, Spaeth D, Laguerre B, Caffo O, Deville JL, Beuzeboc P, Hasbini A, Gross-Goupil M, Helissey C, Bennamoun M, Hardy-Bessard AC, Oudard S. Thibault C, et al. Eur J Cancer. 2018 Jul;97:41-48. doi: 10.1016/j.ejca.2018.03.008. Epub 2018 Apr 7. Eur J Cancer. 2018. PMID: 29636272
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.
Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain SA, Fléchon A, Bamias A, Yu EY, van der Heijden MS, Matsubara N, Alekseev B, Necchi A, Géczi L, Ou YC, Coskun HS, Su WP, Bedke J, Gakis G, Percent IJ, Lee JL, Tucci M, Semenov A, Laestadius F, Peer A, Tortora G, Safina S, Garcia Del Muro X, Rodriguez-Vida A, Cicin I, Harputluoglu H, Tagawa ST, Vaishampayan U, Aragon-Ching JB, Hamid O, Liepa AM, Wijayawardana S, Russo F, Walgren RA, Zimmermann AH, Hozak RR, Bell-McGuinn KM, Powles T; RANGE study investigators. Petrylak DP, et al. Lancet Oncol. 2020 Jan;21(1):105-120. doi: 10.1016/S1470-2045(19)30668-0. Epub 2019 Nov 18. Lancet Oncol. 2020. PMID: 31753727 Free PMC article. Clinical Trial.
Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database.
Delanoy N, Hardy-Bessard AC, Efstathiou E, Le Moulec S, Basso U, Birtle A, Thomson A, Krainer M, Guillot A, De Giorgi U, Hasbini A, Daugaard G, Bahl A, Chowdhury S, Caffo O, Beuzeboc P, Spaeth D, Eymard JC, Fléchon A, Alexandre J, Helissey C, Butt M, Priou F, Lechevallier E, Deville JL, Gross-Goupil M, Morales R, Thiery-Vuillemin A, Gavrikova T, Barthélémy P, Sella A, Fizazi K, Ferrero JM, Laguerre B, Thibault C, Hans S, Oudard S. Delanoy N, et al. Among authors: thibault c. Eur J Cancer. 2020 Jan;125:153-163. doi: 10.1016/j.ejca.2019.10.030. Epub 2019 Nov 29. Eur J Cancer. 2020. PMID: 31787484
Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma.
Fischer S, Tandstad T, Cohn-Cedermark G, Thibault C, Vincenzi B, Klingbiel D, Albany C, Necchi A, Terbuch A, Lorch A, Aparicio J, Heidenreich A, Hentrich M, Wheater M, Langberg CW, Ståhl O, Fankhauser CD, Hamid AA, Koutsoukos K, Shamash J, White J, Bokemeyer C, Beyer J, Gillessen S; Global Germ-Cell Cancer Group. Fischer S, et al. Among authors: thibault c. J Clin Oncol. 2020 Apr 20;38(12):1322-1331. doi: 10.1200/JCO.19.01876. Epub 2019 Dec 26. J Clin Oncol. 2020. PMID: 31877087 Free PMC article.
Health-related Quality of Life in Patients with Advanced Prostate Cancer: A Systematic Review.
Kretschmer A, Ploussard G, Heidegger I, Tsaur I, Borgmann H, Surcel C, Mathieu R, de Visschere P, Valerio M, van den Bergh RCN, Marra G, Thibault C, Ost P, Gandaglia G, Tilki D; EAU-YAU Prostate Cancer Working Party. Kretschmer A, et al. Among authors: thibault c. Eur Urol Focus. 2021 Jul;7(4):742-751. doi: 10.1016/j.euf.2020.01.017. Epub 2020 Feb 20. Eur Urol Focus. 2021. PMID: 32089495 Review.
Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review.
Marra G, Valerio M, Heidegger I, Tsaur I, Mathieu R, Ceci F, Ploussard G, van den Bergh RCN, Kretschmer A, Thibault C, Ost P, Tilki D, Kasivisvanathan V, Moschini M, Sanchez-Salas R, Gontero P, Karnes RJ, Montorsi F, Gandaglia G; EAU-YAU Prostate Cancer Working Party. Marra G, et al. Among authors: thibault c. Eur Urol Oncol. 2020 Oct;3(5):565-581. doi: 10.1016/j.euo.2020.08.005. Epub 2020 Sep 12. Eur Urol Oncol. 2020. PMID: 32933887
338 results